|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021469,
umls-concept:C0021755,
umls-concept:C0026473,
umls-concept:C0079411,
umls-concept:C0086418,
umls-concept:C0115231,
umls-concept:C0205314,
umls-concept:C0679622,
umls-concept:C1280500,
umls-concept:C1533691,
umls-concept:C1999216
|
|
pubmed:dateCreated |
1991-8-9
|
|
pubmed:abstractText |
E5090 is an orally active inhibitor of IL-1 generation, being converted in vivo into the pharmacologically active deacetylated form (DA-E5090). In vitro effects of DA-E5090 on the generation of IL-1 by human monocytes stimulated with LPS were examined. DA-E5090 inhibited both IL-1 alpha and IL-1 beta generation by human monocytes stimulated with 1 microgram/ml of LPS in a dose dependent-manner (1-10 microM), as determined by LAF assay and ELISA. Northern blotting analysis indicated that DA-E5090 inhibits transcription of IL-1 alpha and IL-1 beta m-RNAs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0379-0363
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
225-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:2069091-Acrylates,
pubmed-meshheading:2069091-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:2069091-Blotting, Northern,
pubmed-meshheading:2069091-Gene Expression,
pubmed-meshheading:2069091-Humans,
pubmed-meshheading:2069091-Interleukin-1,
pubmed-meshheading:2069091-Lipopolysaccharides,
pubmed-meshheading:2069091-Monocytes,
pubmed-meshheading:2069091-Naphthols,
pubmed-meshheading:2069091-RNA, Messenger
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
A novel inhibitor of IL-1 generation, E5090: in vitro inhibitory effects on the generation of IL-1 by human monocytes.
|
|
pubmed:affiliation |
Eisai Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan.
|
|
pubmed:publicationType |
Journal Article,
In Vitro
|
